Last updated 2026-06-18
- Raised $7M funding round, May 2025
Total raised
$7.0M
Last: 2025-05
Stage
Seed
Founded
2023
Headcount
7
HQ
Petah Tikva, Israel
Sector
Health Tech & Life Sciences
About
ImmuneWalk Therapeutics is a private clinical-stage company focused on development of novel therapies for chronic inflammatory diseases. The company's Monocyte Targeting Technology (MTT) is designed to selectively block the migration of monocytes from the blood stream into inflamed tissues. With clear disease-modifying activity in models of Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease and Non- Alcoholic Steatohepatitis, in addition to proof-of-concept from patient’s cells, The company is advancing its solution (IW-601) to a Ph1 clinical trial.
Funding history · 1 round · $7.0M total
2025-05
$7.0M
Q&A
- What is ImmuneWalk Therapeutics' primary focus?
- ImmuneWalk Therapeutics is a clinical-stage company focused on developing novel therapies for chronic inflammatory diseases by preventing myeloid cells from entering inflamed tissue.
- When was ImmuneWalk Therapeutics founded?
- ImmuneWalk Therapeutics was founded in October 2023.
- How much funding has ImmuneWalk Therapeutics raised to date?
- ImmuneWalk Therapeutics has raised a total of $7,000,000.
- When did ImmuneWalk Therapeutics complete its last funding round?
- ImmuneWalk Therapeutics completed a funding round in May 2025, raising $7,000,000.
- What is the current employee count for ImmuneWalk Therapeutics?
- ImmuneWalk Therapeutics has 1-10 employees.
- Who are the co-founders of ImmuneWalk Therapeutics?
- The co-founders of ImmuneWalk Therapeutics are Prof Dror Harats (CEO), Sam Backenorth (CFO), and Erez Feige (COO).
- What is ImmuneWalk Therapeutics' core technology?
- ImmuneWalk Therapeutics utilizes Monocyte Targeting Technology (MTT) to selectively block the migration of monocytes from the bloodstream into inflamed tissues.
- What is the current product stage of ImmuneWalk Therapeutics' solution IW-601?
- ImmuneWalk Therapeutics is advancing its solution, IW-601, to a Phase 1 clinical trial.
Team · 3
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical Biotechnology
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatients
Business model
B2C
Tags
immuno-theraphybiopharmaceutical
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | immunewalk.com/ |
|---|---|
| X / Twitter | immunewalk |
Identifiers & details
| Founded | 2023-10 |
|---|---|
| Employees (exact) | 7 |
Radar intelligence
Patents
| EPO | 5 |
|---|
Web history (Wayback)
| Domain | immunewalk.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|